ESR1 and breast cancer: In ER+/HER2− cell lines and breast cancer PDX models, CTx‐648 demonstrated potent and selective inhibitory activity against the KAT domains of KAT6A, yielding strong and tolerable on‐target in vivo efficacy involving tumor regression with minimal toxicity [180].